Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Intangibles: 2010-2024

Historic Intangibles for Ligand Pharmaceuticals (LGND) over the last 15 years, with Dec 2024 value amounting to $266.6 million.

  • Ligand Pharmaceuticals' Intangibles fell 15.05% to $233.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $233.5 million, marking a year-over-year decrease of 15.05%. This contributed to the annual value of $266.6 million for FY2024, which is 11.00% down from last year.
  • According to the latest figures from FY2024, Ligand Pharmaceuticals' Intangibles is $266.6 million, which was down 11.00% from $299.6 million recorded in FY2023.
  • Over the past 5 years, Ligand Pharmaceuticals' Intangibles peaked at $595.3 million during FY2020, and registered a low of $266.6 million during FY2024.
  • Moreover, its 3-year median value for Intangibles was $299.6 million (2023), whereas its average is $302.9 million.
  • In the last 5 years, Ligand Pharmaceuticals' Intangibles surged by 182.89% in 2020 and then crashed by 36.73% in 2021.
  • Yearly analysis of 5 years shows Ligand Pharmaceuticals' Intangibles stood at $595.3 million in 2020, then slumped by 36.73% to $376.7 million in 2021, then dropped by 9.09% to $342.5 million in 2022, then fell by 12.51% to $299.6 million in 2023, then dropped by 11.00% to $266.6 million in 2024.